JOHN KELLY: Open Payments
NPI 1558704775 · MASSAPEQUA, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,921 in 192 payments from 27 companies in 2025. Trend: 2023 $3,201 · 2024 $3,897 · 2025 $3,921
Food & beverage: $3,921
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 28 | $591 |
| ABBVIE INC. | 35 | $500 |
| PFIZER INC. | 22 | $448 |
| Amgen Inc. | 7 | $256 |
| Gilead Sciences, Inc. | 11 | $224 |
| GlaxoSmithKline, LLC. | 12 | $221 |
| Novo Nordisk Inc | 9 | $177 |
| Abbott Laboratories | 9 | $148 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 8 | $147 |
| Esperion Therapeutics, Inc. | 8 | $143 |
Products named: AIRSUPRA, NURTEC ODT, OTEZLA, UBRELVY, FARXIGA, TRELEGY ELLIPTA, FREESTYLE LIBRE 3, XIFAXAN.
Industry payments across NY — which companies pay providers there.
